Literature DB >> 27188858

Association of IL1Β (-511 A/C) and IL6 (-174 G > C) polymorphisms with higher disease activity and clinical pattern of psoriatic arthritis.

N Cubino1, C Montilla2,3, R Usategui-Martín4, C Cieza-Borrela4, T Carranco1, I Calero-Paniagua1, A Quesada1, J D Cañete5, R Queiro6, M D Sánchez1, C Hidalgo1, O Martínez1, J Del Pino-Montes1, A Díaz-Álvarez7, R González-Sarmiento4,8.   

Abstract

The objective of this study is to analyze whether IL1β (-511G > A) and IL6 (-174 G > C) polymorphisms are associated with inflammatory activity, radiographic damage or clinical pattern of psoriatic arthritis (PsA). One hundred twenty-five patients classified as PsA according to the Classification of Psoriatic Arthritis (CASPAR) criteria were included. Patients were stratified according to their clinical pattern at inclusion as peripheral, axial, or mixed involvement. Disease activity in peripheral or mixed forms was measured using the number of swollen and tender joints, pain analog visual scale, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and disease activity score 28 (DAS28). Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was used for axial and mixed forms, as were pain visual analog scale, ESR and CRP. Radiographic damage was evaluated using a modified Sharp score and modified stoke ankylosing spondylitis spinal score (SASSSm). The polymorphisms for the promoter region of IL1β (-511 G/A) and IL-6 (-174 G/C) were analyzed. The G allele of IL1B (-511G/A) polymorphism was associated with higher peripheral joint disease activity (OR 3.13; p < 0.0004; CI 95 % 1.43-6.82, p (corrected) <0.008), while the G allele of the IL6 (174G > C) polymorphism presented a strong trend to be associated with peripheral forms (70.86 %) (OR 1.89; p < 0.03; CI 95 % 1.06-3.39, p-corrected 0.05). In addition, this allele showed a lower association with HLA-B27 (15.78 %) compared with C allele (28.57 %) (OR 0.469; p = 0.02; CI 95 % 0.238-0.923, p-corrected 0.03). This study suggests that the G allele polymorphism of IL1B (-511 A/C) is associated with higher peripheral joint disease activity. On the other hand, the IL6 (-174 G/C) polymorphism showed a strong trend to be associated with the peripheral pattern of PsA.

Entities:  

Keywords:  Genetics; IL1β; IL6; Polymorphism; Psoriatic arthritis; SNP

Mesh:

Substances:

Year:  2016        PMID: 27188858     DOI: 10.1007/s10067-016-3301-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  26 in total

1.  An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX).

Authors:  Norma Jung; Matthias Hellmann; Reimund Hoheisel; Clara Lehmann; Ingo Haase; Andreas Perniok; Michael Hallek; Andrea Rubbert
Journal:  Clin Rheumatol       Date:  2010-06-09       Impact factor: 2.980

2.  Influence of HLA-B27 on the clinical presentation of psoriatic arthritis.

Authors:  Nicola Dalbeth; Joanne L Dockerty; Lyn Williamson
Journal:  J Rheumatol       Date:  2003-11       Impact factor: 4.666

3.  Synovial fluid cytokines in patients with rheumatoid arthritis or other arthritic lesions.

Authors:  H Lettesjö; E Nordström; H Ström; B Nilsson; B Glinghammar; L Dahlstedt; E Möller
Journal:  Scand J Immunol       Date:  1998-09       Impact factor: 3.487

4.  Investigation of IL1, VEGF, PPARG and MEFV genes in psoriatic arthritis susceptibility.

Authors:  John Bowes; Pauline Ho; Edward Flynn; Salma Salah; Neil McHugh; Oliver FitzGerald; Jonathan Packham; Ann W Morgan; Philip S Helliwell; Ian N Bruce; Anne Barton
Journal:  Ann Rheum Dis       Date:  2011-07-28       Impact factor: 19.103

5.  Interleukin 1alpha, interleukin 1beta and interleukin 1 receptor gene polymorphisms in psoriatic arthritis.

Authors:  J S Ravindran; P Owen; A Lagan; J Lewis; E Korendowych; K Welsh; N McHugh
Journal:  Rheumatology (Oxford)       Date:  2003-07-30       Impact factor: 7.580

6.  Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2.

Authors:  D van der Heijde; A Kavanaugh; D D Gladman; C Antoni; G G Krueger; C Guzzo; B Zhou; L T Dooley; K de Vlam; P Geusens; C Birbara; D Halter; A Beutler
Journal:  Arthritis Rheum       Date:  2007-08

7.  Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis?

Authors:  G-M Alenius; C Eriksson; S Rantapää Dahlqvist
Journal:  Clin Exp Rheumatol       Date:  2009 Jan-Feb       Impact factor: 4.473

8.  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.

Authors:  D Fishman; G Faulds; R Jeffery; V Mohamed-Ali; J S Yudkin; S Humphries; P Woo
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

9.  Polymorphisms in genes controlling inflammation and tissue repair in rheumatoid arthritis: a case control study.

Authors:  Marieke Emonts; Mieke J M W Hazes; Jeanine J Houwing-Duistermaat; Christa E van der Gaast-de Jongh; Lisette de Vogel; Huub K H Han; Jacques M G W Wouters; Jon D Laman; Radboud J E M Dolhain
Journal:  BMC Med Genet       Date:  2011-03-07       Impact factor: 2.103

10.  Transforming growth factor β 869C/T and interleukin 6 -174G/C polymorphisms relate to the severity and progression of bone-erosive damage detected by ultrasound in rheumatoid arthritis.

Authors:  Fulvia Ceccarelli; Carlo Perricone; Martina Fabris; Cristiano Alessandri; Annamaria Iagnocco; Cinzia Fabro; Elena Pontarini; Salvatore De Vita; Guido Valesini
Journal:  Arthritis Res Ther       Date:  2011-07-08       Impact factor: 5.156

View more
  5 in total

1.  Influence of TNF and IL17 Gene Polymorphisms on the Spondyloarthritis Immunopathogenesis, Regardless of HLA-B27, in a Brazilian Population.

Authors:  Marco A Rocha Loures; Luciana C Macedo; Denise M Reis; Camila F Oliveira; Jean L Meneguetti; Gabriela F Martines; Janisleya S F Neves; Eliana de Souza; Ana M Sell; Jeane E L Visentainer
Journal:  Mediators Inflamm       Date:  2018-04-19       Impact factor: 4.711

2.  The use of leukocytes' secretome to individually target biological therapy in autoimmune arthritis: a case report.

Authors:  Patrice E Poubelle; Nathalie Pagé; Marie-Pier Longchamps; Natalia Sampaio Moura; David B Beck; Ivona Aksentijevich; Philippe A Tessier; Martin Pelletier
Journal:  Clin Transl Med       Date:  2019-06-05

3.  Predicting clinically promising therapeutic hypotheses using tensor factorization.

Authors:  Jin Yao; Mark R Hurle; Matthew R Nelson; Pankaj Agarwal
Journal:  BMC Bioinformatics       Date:  2019-02-08       Impact factor: 3.169

4.  Relationship Between Interleukin-6 -174G/C Genetic Variant and Efficacy of Methotrexate Treatment in Psoriatic Arthritis Patients.

Authors:  Renata Sokolik; Milena Iwaszko; Jerzy Świerkot; Barbara Wysoczańska; Lucyna Korman; Piotr Wiland; Katarzyna Bogunia-Kubik
Journal:  Pharmgenomics Pers Med       Date:  2021-01-28

Review 5.  Interleukin-1 Beta-A Friend or Foe in Malignancies?

Authors:  Rebekka Bent; Lorna Moll; Stephan Grabbe; Matthias Bros
Journal:  Int J Mol Sci       Date:  2018-07-24       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.